Bionyra Pharma emerged from stealth after raising $165 million in an oversubscribed Series A to develop next-generation biologics for severe immunological and inflammatory diseases. The round was co-led by Jeito Capital and Sofinnova Partners, with participation from Sanofi Ventures, Arkin Bio, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures. Co-founder and CEO Frédéric Marrache, MD, PhD—formerly at Sanofi working on immune-mediated drug development—will lead the company’s clinical-stage efforts. The financing also brings board representation from multiple investors, including Anta Gkelou and Laia Crespo, signaling early alignment with platform-building expectations in inflammatory pipelines. The launch underscores continuing investor appetite for differentiation in inflammation biologics, especially when teams combine target/pathway mapping experience with a fundable early clinical plan.